-
At A Glance -
Education
-
Find Me On https://cinj.org/shridar-ganesan-md-phd I came to Rutgers Cancer Institute of New Jersey in 2005 from the Dana-Farber Cancer Institute/Harvard Medical School where I was an instructor in medicine and staff physician. I started my medical training at Yale University, where I graduated from with both an MD and a PhD in cell biology. I then completed a medical residency at the Brigham and Women’s Hospital in Boston and served as a Chief Medical Resident. This was followed by a fellowship in medical oncology at the Dana-Farber Cancer Institute.
With a research interest in breast cancer biology and DNA repair, I am currently exploring how DNA repair defects in cancers can be exploited to develop novel effective treatments. I am also active in applying next-generation sequencing technology to identify specific genomic changes in cancers that can be therapeutically targeted. We work closely with computational scientists in interpreting large scale cancer genome data As a physician/scientist I run a basic science laboratory focused on cancer genomics and breast cancer biology and also see patients in the Stacy Goldstein Breast Cancer Center. I also run the RCINJ Molecular Tumor Board. In the clinic, I work collaboratively with experts across multi-disciplines and have the opportunity to put theory into practice as we aim to develop the next generation of targeted treatments for breast cancer. Working with a team of radiation oncologists, surgical oncologists, nurses, social workers, genetic specialists and others, I help patients understand their specific disease and their treatment options so that they can make informed decisions.
I'm also also affiliated with RWJ University Hospital.
Related Articles - Nov 26, 2023 - Dr Ganesan on the Use of ctDNA Assays For MRD Detection in Cancer Care
- Aug 01, 2023 - Rutgers Cancer Institute of New Jersey Receives Grants to Support Ongoing Oncology Research
- Aug 10, 2022 - Unraveling of Genetic Mechanism Behind Tumor Formation May Improve Targeted Treatment for Cancer Patients
Clinical Interests Breast cancer, BRCA1/2, triple-negative breast cancer, breast cancer biology, clinical trials, rare cancers, precision medicine
Awards - Hero Award, Triple Negative Breast Cancer Foundation
- Sidney Kimmel Foundation, Kimmel Scholar Award, 2006
- National Cancer Institute, Howard Temin Award, 2004
- Howard Hughes Medical Institute, Postdoctoral Research Fellowship, 1999
- 2024 Excellence in Research Award